Can Lilly's Abemaciclib Overcome Third Place Finish In CDK4/6 Race?

Lilly reported positive top-line results for abemaciclib in the Phase III MONARCH 2 trial and revealed a regulatory strategy that has it rapidly racing after competing CDK4/6 inhibitors already approved for certain breast cancer patients.